Drugs / TR128
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05751356 | Feb 2024 → Aug 2025 | neoplastic disease or syndrome | Tarapeutics Science Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05751356 ↗ |
| Route | Oral | “TR128 is given orally daily.” NCT05751356 ↗ |